AMAG Pharmaceuticals, Inc.  

(Public, NASDAQ:AMAG)   Watch this stock  
Find more results for AMAG
23.13
+0.36 (1.58%)
After Hours: 22.65 -0.48 (-2.08%)
Feb 9, 4:30PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 22.21 - 24.00
52 week 20.85 - 77.73
Open 22.33
Vol / Avg. 893,133.00/1.01M
Mkt cap 771.85M
P/E 4.97
Div/yield     -
EPS 4.66
Shares 34.70M
Beta 0.85
Inst. own 123%
Feb 24, 2016
AMAG Pharmaceuticals Inc at RBC Capital Markets Healthcare Conference - 8:30AM EST - Add to calendar
Feb 17, 2016
Q4 2015 AMAG Pharmaceuticals Inc Earnings Release - 9:30AM EST - Add to calendar
Feb 17, 2016
Q4 2015 AMAG Pharmaceuticals Inc Earnings Call - 8:00AM EST - Add to calendar
Feb 10, 2016
AMAG Pharmaceuticals Inc at Leerink Partners Global Healthcare Conference - 1:50PM EST - Add to calendar
Jan 13, 2016
AMAG Pharmaceuticals Inc at JPMorgan Healthcare Conference - Q&A Session - Webcast
Jan 13, 2016
AMAG Pharmaceuticals Inc at JPMorgan Healthcare Conference - Webcast
Jan 11, 2016
Preliminary Q4 2015 AMAG Pharmaceuticals Inc Earnings Release
Nov 18, 2015
AMAG Pharmaceuticals Inc at Jefferies Global Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -21.41% 109.19%
Operating margin -12.31% -3.08%
EBITD margin - 11.78%
Return on average assets -3.94% 16.42%
Return on average equity -10.11% 42.96%
Employees 257 -
CDP Score - -

Address

1100 Winter St
WALTHAM, MA 02451-1427
United States - Map
+1-617-4983300 (Phone)
+1-617-4993361 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on maternal health, anemia and cancer supportive care. The Company markets Makena (hydroxyprogesterone caproate injection), Feraheme (ferumoxytol) Injection for Intravenous (IV) use and MuGard Mucoadhesive Oral Wound Rinse. Feraheme is an IV iron replacement therapy for the treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD). Feraheme is approved for marketing in the United States. Makena is a drug indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth. MuGard is indicated for the management of oral mucositis/stomatitis and all types of oral wounds, including aphthous ulcers/canker sores and traumatic ulcers, such as those caused by oral surgery or ill-fitting dentures or braces.

Officers and directors

Gino Santini Chairman of the Board
Age: 58
Bio & Compensation  - Reuters
Frank E. Thomas President, Interim Principal Financial Officer, Chief Operating Officer, Interim Principal Accounting Officer
Age: 45
Bio & Compensation  - Reuters
William K. Heiden Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
Nicholas Grund Executive Vice President, Chief Commercial Officer
Bio & Compensation  - Reuters
Joseph Vittiglio Senior Vice President, General Counsel, Secretary
Age: 43
Bio & Compensation  - Reuters
Edward Jordan Senior Vice President - Sales and Marketing
Age: 47
Bio & Compensation  - Reuters
Linda Lennox Vice President of Investor Relations, & Corporate Communications
Bio & Compensation  - Reuters
Katie Payne Vice President - External Affairs.
Bio & Compensation  - Reuters
Aaron Pelta Vice President - Business Development
Bio & Compensation  - Reuters
John A. Fallon M.D. Director
Age: 68
Bio & Compensation  - Reuters